The ethical controversy surrounding stem cell research does
not reach the International Stem Cell Corp. as it employs non-embryonic cells
(unfertilized) for exploring and attempting to treat different diseases. The
company has developed the first collection of non-embryonic human stem cells
that are stored in the UniStemCell Bank. When properly stimulated, the
unfertilized eggs begin dividing into usable cells called human parthenogenetic
stem cells (hpSC). The process, called parthenogenesis, creates stem cells that
are self-renewing and have high potential for being compatible with a large
portion of the population. A single cell line can treat millions of people with
a low risk of immune rejection, a common issue in stem cell therapies. The
company intends to use this system on eye, nervous system, and liver diseases
with high expectations for successful results.
The controversy surrounding embryonic stem cell research
begins with the view that life starts at conception with the embryo. The
formation of a human stem cell line means the destruction of a human embryo.
Therefore, the rights and status of an embryo are called into question.
Fortunately, the International Stem Cell Corp. side steps
this controversy by using unfertilized embryos in its research. Stem cells have
the capability of becoming any and all types of cells in the body, making them
invaluable when combating degenerative diseases. However, the use of
non-embryonic adult stem cells produces the possibility of immune rejection
while embryonic cells lessen that chance. The company’s production of human
leukocyte antigen genes (HLA) from parthenogenesis greatly diminishes this risk
while keeping an ethical advantage.
The rapid division of these cells into usable regenerative
ones means potentially effective cellular replacement therapies. The company
has developed treatments for liver and retinal diseases that replace aged or
damaged cells with newer ones. The company also recently announced its
progression with clinical trials in treating Parkinson’s disease in Australia.
The International Stem Cell Corp. continues its goal of
developing innovative restorative stem cell treatments for diseases that cause
deterioration.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
